🎉 M&A multiples are live!
Check it out!

Allergy Therapuetics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Allergy Therapuetics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Allergy Therapuetics Overview

About Allergy Therapuetics

Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergies with aluminum-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany, Austria, Netherlands, and Switzerland.


Founded

2004

HQ

United Kingdom of Great Britain and Northern Ireland
Employees

602

Financials

LTM Revenue $73.9M

LTM EBITDA -$25.7M

EV

$352M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Allergy Therapuetics Financials

Allergy Therapuetics has a last 12-month revenue of $73.9M and a last 12-month EBITDA of -$25.7M.

In the most recent fiscal year, Allergy Therapuetics achieved revenue of $71.1M and an EBITDA of -$39.6M.

Allergy Therapuetics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Allergy Therapuetics valuation multiples based on analyst estimates

Allergy Therapuetics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $76.7M $71.1M XXX XXX XXX
Gross Profit $63.7M $42.8M XXX XXX XXX
Gross Margin 83% 60% XXX XXX XXX
EBITDA -$45.2M -$39.6M XXX XXX XXX
EBITDA Margin -59% -56% XXX XXX XXX
Net Profit -$17.7M -$55.5M XXX XXX XXX
Net Margin -23% -78% XXX XXX XXX
Net Debt n/a $16.0M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Allergy Therapuetics Stock Performance

As of April 15, 2025, Allergy Therapuetics's stock price is GBP 0 (or $0).

Allergy Therapuetics has current market cap of GBP 250M (or $322M), and EV of GBP 273M (or $352M).

See Allergy Therapuetics trading valuation data

Allergy Therapuetics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$352M $322M XXX XXX XXX XXX $-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Allergy Therapuetics Valuation Multiples

As of April 15, 2025, Allergy Therapuetics has market cap of $322M and EV of $352M.

Allergy Therapuetics's trades at 4.8x LTM EV/Revenue multiple, and -13.7x LTM EBITDA.

Analysts estimate Allergy Therapuetics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Allergy Therapuetics and 10K+ public comps

Allergy Therapuetics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $352M XXX XXX XXX
EV/Revenue 4.8x XXX XXX XXX
EV/EBITDA -11.3x XXX XXX XXX
P/E -6.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -9.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Allergy Therapuetics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Allergy Therapuetics Valuation Multiples

Allergy Therapuetics's NTM/LTM revenue growth is 27%

Allergy Therapuetics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, Allergy Therapuetics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Allergy Therapuetics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Allergy Therapuetics and other 10K+ public comps

Allergy Therapuetics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -7% XXX XXX XXX XXX
EBITDA Margin -43% XXX XXX XXX XXX
EBITDA Growth -12% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -15% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $0.1M XXX XXX XXX XXX
S&M Expenses to Revenue 35% XXX XXX XXX XXX
G&A Expenses to Revenue 41% XXX XXX XXX XXX
R&D Expenses to Revenue 41% XXX XXX XXX XXX
Opex to Revenue 116% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Allergy Therapuetics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Allergy Therapuetics M&A and Investment Activity

Allergy Therapuetics acquired  XXX companies to date.

Last acquisition by Allergy Therapuetics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Allergy Therapuetics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Allergy Therapuetics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Allergy Therapuetics

When was Allergy Therapuetics founded? Allergy Therapuetics was founded in 2004.
Where is Allergy Therapuetics headquartered? Allergy Therapuetics is headquartered in United Kingdom of Great Britain and Northern Ireland.
How many employees does Allergy Therapuetics have? As of today, Allergy Therapuetics has 602 employees.
Who is the CEO of Allergy Therapuetics? Allergy Therapuetics's CEO is Mr. Manuel Llobet.
Is Allergy Therapuetics publicy listed? Yes, Allergy Therapuetics is a public company listed on LON.
What is the stock symbol of Allergy Therapuetics? Allergy Therapuetics trades under AGY ticker.
When did Allergy Therapuetics go public? Allergy Therapuetics went public in 2004.
Who are competitors of Allergy Therapuetics? Similar companies to Allergy Therapuetics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Allergy Therapuetics? Allergy Therapuetics's current market cap is $322M
What is the current revenue of Allergy Therapuetics? Allergy Therapuetics's last 12-month revenue is $73.9M.
What is the current EBITDA of Allergy Therapuetics? Allergy Therapuetics's last 12-month EBITDA is -$25.7M.
What is the current EV/Revenue multiple of Allergy Therapuetics? Current revenue multiple of Allergy Therapuetics is 4.8x.
What is the current EV/EBITDA multiple of Allergy Therapuetics? Current EBITDA multiple of Allergy Therapuetics is -13.7x.
What is the current revenue growth of Allergy Therapuetics? Allergy Therapuetics revenue growth between 2023 and 2024 was -7%.
Is Allergy Therapuetics profitable? Yes, Allergy Therapuetics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.